首页> 外文期刊>International Urology and Nephrology >Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience
【24h】

Intravesical application of platelet-rich plasma in patients with persistent haemorrhagic cystitis after hematopoietic stem cell transplantation: a single-centre preliminary experience

机译:血小板血小板血浆患者血液成分干细胞移植后持续出血性膀胱炎患者的膀胱内应用:单中心初步体验

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Purpose Haemorrhagic cystitis (HC) after allogeneic transplantation (HSCT) is a condition characterized by diffuse inflammation and bleeding from the bladder mucosa. Treatment of HC is not standardized and clinical Guidelines are elusive. The aim of this study was to evaluate the safety and efficacy of intravesical treatment with platelet-rich plasma (PRP) in patients with HC after allogenic HSCT. Methods Data from ten consecutive patients with BK virus-induced HC between 2013 and 2017 were collected. HC was classified into four grades. Inclusion criteria were (a) grade 3 or 4 BKV-induced HC after allogenic HSCT; (b) HC refractory to conservative therapy. All patients underwent transurethral cystoscopy and PRP treatment under general anaesthesia. Results Mean patients' age was 33.6 years. Four patients (40%) presented a grade 3 BKV-induced HC and six patients (60%) a grade 4. No intraoperative complications occurred. Postoperative complications were recorded in six patients: three patients required blood transfusion while three patients endovenous antibiotic therapy. Median time to catheter removal was 6 days (IQR 2-10). Median length of hospitalization was 35 days (IQR 6-73). At 30 days after surgery, a three-way catheter was repositioned in one patient for grade 4 haematuria, six patients had a complete response, and three a partial response. Conclusions Our preliminary experience suggests that intravesical administration of PRP should be considered as a feasible and safe option for the treatment of BK-induced HC after HSCT. Future studies are needed to assess its potential value in other forms of haemorrhagic cystitis.
机译:单项式移植(HSCT)后的目的出血膀胱炎(HC)是由弥漫性炎症和从膀胱粘膜出血的病症。 HC的治疗不是标准化,临床指南是难以捉摸的。本研究的目的是评估含有HC患者的血小板血浆(PRP)的安全性和疗效,同种异体HSCT后HC。方法收集2013年至2017年间BK病毒诱导的HC的连续十个患者的数据。 HC被分为四个等级。包含标准是(a)3级或4级BKV诱导的HC后同种异体的HSCT; (b)保守治疗的HC耐火材料。所有患者均在全身麻醉下进行过尿道膀胱镜检查和PRP治疗。结果意味着患者年龄为33.6岁。四名患者(40%)呈现3级BKV诱导的HC和6名患者(60%)级别4级。没有发生术中并发症。术后并发症患有六位患者:三名患者需要输血,而三名患者的统治抗生素治疗。中位时间去除导管的时间为6天(IQR 2-10)。中位数的住院时间为35天(IQR 6-73)。在手术后30天,在4级患者中重新定位三通导管,六级血尿,六名患者具有完整的反应,以及三个部分反应。结论我们的初步经验表明,PRP的膀胱内施用应被视为HSCT后治疗BK诱导的HC的可行和安全的选择。需要进行未来的研究来评估其其他形式的出血性膀胱炎的潜在价值。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号